Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
21. Juni 2024 17:00 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and...
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
24. Mai 2024 16:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
23. Mai 2024 17:00 ET
|
Iovance Biotherapeutics, Inc.
Lifileucel TIL Cell Therapy in Combination with Pembrolizumab DemonstratesDeep, Durable Responses in Frontline Advanced Melanoma Patientsin IOV-COM-202 Clinical Study ASCO Oral Presentation to...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
17. Mai 2024 17:15 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and...
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
09. Mai 2024 16:01 ET
|
Iovance Biotherapeutics, Inc.
Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Patients Enrolled Across More Than 40 Current Authorized Treatment...
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
01. Mai 2024 06:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
Iovance Biotherapeutics to Present at Upcoming Conferences
30. April 2024 06:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
24. April 2024 16:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
19. April 2024 17:15 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
22. März 2024 17:30 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and...